ALTSTATION.IO

Corteva, Inc. (CTVA) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$72.28

Change

-0.27%

Market Cap

$48.84B

Avg Volume

3.7M

Company Overview

Corteva, Inc. (CTVA) is a leading player in the agricultural input sector, providing a wide range of products designed to enhance crop yields and protect against pests and diseases. Founded in 2018 and headquartered in Indianapolis, Corteva operates through two main segments: Seed and Crop Protection. The Seed segment offers advanced germplasm and traits that improve crop performance, while the Crop Protection segment supplies herbicides, insecticides, and nitrogen stabilizers. Their customers are primarily farmers and agricultural enterprises seeking to optimize productivity and profitability.

Corteva holds a strong competitive position in the global agricultural market, competing against giants like Bayer and Syngenta. As a market leader in seed technology and crop protection solutions, Corteva benefits from a robust research and development pipeline that drives innovation. However, it faces challenges from increasing competition and volatile market conditions, such as fluctuating commodity prices and climate change impacts. The ability to adapt to these dynamics is crucial in maintaining its edge.

Currently, Corteva is in a growth phase, focusing on expanding its product offerings and enhancing sustainability practices. Recent milestones include the launch of new seed varieties and environmentally friendly crop protection products, aimed at addressing farmer concerns about sustainability. The company’s strategic emphasis on digital agriculture and precision farming adds another layer of growth potential, aligning with industry trends toward data-driven farming solutions.

Key Financials

Market Cap

$48.84B

Revenue

$17.40B

EBITDA

$3.82B

Gross Margin

47.3%

Profit Margin

6.3%

Revenue Growth

-1.7%

Total Cash

$4.53B

Total Debt

$2.58B

Free Cash Flow

$2.99B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

41.30

Forward P/E

17.86

Beta

0.74

52-Week High

$77.41

52-Week Low

$53.40

EPS

$1.75

50-Day Avg

$68.61

200-Day Avg

$68.91

Price/Book

2.01

Technical Analysis

Corteva, Inc. (CTVA) exhibits a clear upward trend over the past 52 weeks, increasing from a low near $55 in February to its current price of $72.28, marking a 17.9% gain. Key support is identified around $65, the level from which the stock rebounded multiple times, while resistance is evident at $75, where the stock has struggled to maintain price momentum in recent months. A notable formation is the ascending triangle pattern seen in the latter half of the chart, indicating bullish sentiment as higher lows are established. In the recent weeks, the stock has shown strong momentum, consistently closing near the upper end of its recent range, suggesting increased buying pressure. Currently, at $72.28, the stock is within striking distance of its 52-week high, which implies that a sustained break above this resistance could lead to further gains, while the proximity to key support suggests a cautionary stance if it begins to falter.

Recent News and Developments

Here’s a summary of the latest news and developments for Corteva, Inc

(CTVA) stock in the past week, covering February 1 – February 7, 2026:

Market Update

### Corteva Reports Q4 2025 Earnings, Misses Revenue Estimates but Beats EPS

On February 3, 2026, Corteva, Inc

announced its financial results for the fourth quarter and full-year ended December 31, 2025. The company reported adjusted earnings per share (EPS) of $0.22, surpassing the Zacks Consensus Estimate of $0.21. However, quarterly revenue came in at $3.91 billion, falling short of the $4.24 billion consensus estimate, which the company attributed primarily to seasonal timing shifts of some deliveries into the first quarter of 2026. Corteva also provided an optimistic outlook for fiscal year 2026, forecasting operating EPS of $3.45 to $3.70, exceeding the analyst consensus of $3.33, and operating EBITDA between $4.0 billion and $4.2 billion.

Market Sentiment and Analyst Recommendations

Bull Case

Corteva’s 2026 guidance of $3.45-$3.70 EPS crushes the $3.33 consensus, signaling management confidence in execution. The Bayer licensing deal is a game-changer: $1 billion in earnings upside over a decade and royalty neutrality arriving in 2026 instead of 2028 removes a major headwind. New product launches like Telbek PRO and the potential commercialization of multi-disease resistant corn within 1-2 years give the company genuine growth vectors beyond commodity ag cycles. The balance sheet is solid with $4.53B cash against $2.58B debt, providing flexibility for M&A or shareholder returns. At 41.3x P/E the stock looks expensive on paper, but that multiple compresses meaningfully if the company delivers on $3.65 midpoint EPS guidance. The chart shows an ascending triangle with strong momentum near 52-week highs, and 21 analysts rate it a buy with $81.24 average target, implying 12% upside from current levels.

Bear Case

Revenue contracted 1.7% year-over-year and Q4 missed consensus by $330 million, a meaningful gap blamed on timing shifts. The company is guiding into a lower revenue base while trying to grow earnings per share, which means margin expansion has to be flawless. At $72.28 the stock is already up 17.9% from its 52-week low and trades at the upper end of its range, leaving limited room for error. JP Morgan’s downgrade from Overweight to Neutral despite raising the price target signals analyst caution on momentum and valuation. The ag sector remains cyclical and exposed to commodity prices, weather, and policy changes that Corteva cannot control. If the company stumbles on execution of new products or the Bayer deal doesn’t deliver as promised, multiple compression could be brutal given the current 41.3x P/E. The stock is 6.8% below the analyst target, meaning much of the upside is already priced in.

What to Watch

Monitor Q1 2026 revenue delivery closely to confirm whether Q4’s timing shift into Q1 actually materializes or was an excuse for weakness. Track the Bayer licensing deal’s contribution to earnings throughout 2026 and watch for any announcements that royalty neutrality is delayed. Watch for regulatory approvals on gene-edited crops in Europe, particularly for the multi-disease resistant corn mentioned for commercialization within 1-2 years. If CTVA breaks above the $75 resistance level with volume, the next target is likely the $77-$81 range, validating the bull thesis. Conversely, if the stock falls below $70 support, it signals that guidance optimism isn’t translating to investor confidence and could trigger a retest of $65. Quarterly EPS delivery against the $3.45-$3.70 guidance will be the acid test for whether management’s confidence is justified or just cheerleading. Keep an eye on agricultural commodity prices, particularly corn and soybeans, as input cost inflation could pressure margins if not offset by pricing power.

Analyst Consensus

BUY

Based on 21 analyst opinions

Low Target

$65.00

Mean Target

$81.24

High Target

$90.00

Earnings and Financial Data

Sector

Basic Materials

Industry

Agricultural Inputs

Employees

N/A

Earnings & Dividends

Next Earnings

Feb 03, 2026

EPS (Trailing)

$1.75

Dividend Yield

99.0%

Payout Ratio

40.0%

Frequently Asked Questions

Is CTVA a good stock to buy?

Yes, analysts recommend a BUY rating on Corteva with a target price of $81.24. The stock is currently trading at $72.28, offering potential upside of about 12.5%.

What is CTVA’s price target?

The analyst target for Corteva is $81.24. This represents a potential gain based on its current trading price of $72.28.

Does CTVA pay a dividend?

Yes, Corteva has a dividend yield of 99.0%. This high yield makes it an attractive option for income-focused investors.

What is the P/E ratio for CTVA?

Corteva has a price-to-earnings (P/E) ratio of 41.30, with a forward P/E of 17.86. The forward P/E suggests better earnings potential moving forward compared to its current valuation.

What is CTVA’s market capitalization?

Corteva’s market cap is approximately $48.84 billion. This positions it as a significant player in the agricultural inputs sector, reflecting its strong market presence.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.